Clinical efficacy analysis of cross-line immunotherapy in driver gene-negative advanced non-small cell lung cancer patients
Objective To investigate the clinical efficacy and prognosis of cross-line immunotherapy for driver gene-negative advanced non-small cell lung cancer (NSCLC).Methods Clinical data of patients with advanced NSCLC in Zhongnan Hospital of Wuhan University from June 2019 to December 2023 were retrospect...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of New Medicine
2025-02-01
|
| Series: | Yixue xinzhi zazhi |
| Subjects: | |
| Online Access: | https://yxxz.whuznhmedj.com/futureApi/storage/attach/2502/SAsnnW97URWo1VKYsbGTX5O5s9AqUu0PGI4YdlBb.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849722930410291200 |
|---|---|
| author | WANG Yuankun LU Jiahao HU Jing XIE Conghua |
| author_facet | WANG Yuankun LU Jiahao HU Jing XIE Conghua |
| author_sort | WANG Yuankun |
| collection | DOAJ |
| description | Objective To investigate the clinical efficacy and prognosis of cross-line immunotherapy for driver gene-negative advanced non-small cell lung cancer (NSCLC).Methods Clinical data of patients with advanced NSCLC in Zhongnan Hospital of Wuhan University from June 2019 to December 2023 were retrospectively analyzed. For first-line treatment for the patients, programmed cell death receptor-1 (PD-1) monoclonal antibody combined with platinum-based doublet chemotherapy was adopted, and for second-line treatment, PD-1 monoclonal antibody combined with chemotherapy was used. The Kaplan-Meier method was employed to draw survival curves, and the Log-rank test was used to evaluate the differences in survival. The Cox proportional hazards regression model was used to analyze the risk factors that affect prognosis and subgroup analyses were conducted to explore the impact on patients' prognosis.Results A total of 112 advanced NSCLC patients with negative driver genes were included. The overall response rate (ORR) of cross-line immunotherapy was 20.54%, and the disease control rate (DCR) of cross-line immunotherapy reached 49.11%. The median overall survival (OS) was 26.6 months. The median progression free survival of first-line treatment (PFS-1) was 7.3 months, and that of second-line treatment (PFS-2) was 5.4 months. The subgroup analysis showed that, compared with patients with PFS-1≤10 months, patients with PFS-1>10 months had longer median OS [44.3 months vs. 13.8 months, P |
| format | Article |
| id | doaj-art-47539f30b1db4fab91867b291be0f30f |
| institution | DOAJ |
| issn | 1004-5511 |
| language | zho |
| publishDate | 2025-02-01 |
| publisher | Editorial Office of New Medicine |
| record_format | Article |
| series | Yixue xinzhi zazhi |
| spelling | doaj-art-47539f30b1db4fab91867b291be0f30f2025-08-20T03:11:11ZzhoEditorial Office of New MedicineYixue xinzhi zazhi1004-55112025-02-0135215116110.12173/j.issn.1004-5511.2024080436598Clinical efficacy analysis of cross-line immunotherapy in driver gene-negative advanced non-small cell lung cancer patientsWANG YuankunLU JiahaoHU JingXIE ConghuaObjective To investigate the clinical efficacy and prognosis of cross-line immunotherapy for driver gene-negative advanced non-small cell lung cancer (NSCLC).Methods Clinical data of patients with advanced NSCLC in Zhongnan Hospital of Wuhan University from June 2019 to December 2023 were retrospectively analyzed. For first-line treatment for the patients, programmed cell death receptor-1 (PD-1) monoclonal antibody combined with platinum-based doublet chemotherapy was adopted, and for second-line treatment, PD-1 monoclonal antibody combined with chemotherapy was used. The Kaplan-Meier method was employed to draw survival curves, and the Log-rank test was used to evaluate the differences in survival. The Cox proportional hazards regression model was used to analyze the risk factors that affect prognosis and subgroup analyses were conducted to explore the impact on patients' prognosis.Results A total of 112 advanced NSCLC patients with negative driver genes were included. The overall response rate (ORR) of cross-line immunotherapy was 20.54%, and the disease control rate (DCR) of cross-line immunotherapy reached 49.11%. The median overall survival (OS) was 26.6 months. The median progression free survival of first-line treatment (PFS-1) was 7.3 months, and that of second-line treatment (PFS-2) was 5.4 months. The subgroup analysis showed that, compared with patients with PFS-1≤10 months, patients with PFS-1>10 months had longer median OS [44.3 months vs. 13.8 months, Phttps://yxxz.whuznhmedj.com/futureApi/storage/attach/2502/SAsnnW97URWo1VKYsbGTX5O5s9AqUu0PGI4YdlBb.pdfcross-line immunotherapynon-small cell lung cancerimmune checkpoint inhibitorsprognosisdriver gene-negative |
| spellingShingle | WANG Yuankun LU Jiahao HU Jing XIE Conghua Clinical efficacy analysis of cross-line immunotherapy in driver gene-negative advanced non-small cell lung cancer patients Yixue xinzhi zazhi cross-line immunotherapy non-small cell lung cancer immune checkpoint inhibitors prognosis driver gene-negative |
| title | Clinical efficacy analysis of cross-line immunotherapy in driver gene-negative advanced non-small cell lung cancer patients |
| title_full | Clinical efficacy analysis of cross-line immunotherapy in driver gene-negative advanced non-small cell lung cancer patients |
| title_fullStr | Clinical efficacy analysis of cross-line immunotherapy in driver gene-negative advanced non-small cell lung cancer patients |
| title_full_unstemmed | Clinical efficacy analysis of cross-line immunotherapy in driver gene-negative advanced non-small cell lung cancer patients |
| title_short | Clinical efficacy analysis of cross-line immunotherapy in driver gene-negative advanced non-small cell lung cancer patients |
| title_sort | clinical efficacy analysis of cross line immunotherapy in driver gene negative advanced non small cell lung cancer patients |
| topic | cross-line immunotherapy non-small cell lung cancer immune checkpoint inhibitors prognosis driver gene-negative |
| url | https://yxxz.whuznhmedj.com/futureApi/storage/attach/2502/SAsnnW97URWo1VKYsbGTX5O5s9AqUu0PGI4YdlBb.pdf |
| work_keys_str_mv | AT wangyuankun clinicalefficacyanalysisofcrosslineimmunotherapyindrivergenenegativeadvancednonsmallcelllungcancerpatients AT lujiahao clinicalefficacyanalysisofcrosslineimmunotherapyindrivergenenegativeadvancednonsmallcelllungcancerpatients AT hujing clinicalefficacyanalysisofcrosslineimmunotherapyindrivergenenegativeadvancednonsmallcelllungcancerpatients AT xieconghua clinicalefficacyanalysisofcrosslineimmunotherapyindrivergenenegativeadvancednonsmallcelllungcancerpatients |